Researchers discover how breast cancer mutation in BRCA1 causes protein to self-destruct

February 28, 2017, Virginia Tech
Deborah Kelly, a structural biologist with the Virginia Tech Carilion Research Institute, explained how the BRCA1 gene loses its tumor-fighting potency. Credit: David Hungate/Virginia Tech Carilion

Of the more than 3 million people with breast cancer in the United Stated, about 10 percent carry an inherited mutation in their BRCA1 gene. In health, the gene is responsible for suppressing tumors. In disease, the gene goes terribly awry.

Scientists at the Virginia Tech Carilion Research Institute found that cells can trigger the self-destruction of the tumor-suppressing BRCA1 proteins. They published their results today (Feb. 28) in Scientific Reports, a Nature journal.

"There are different ways in which DNA damage can be repaired. The breast cancer susceptibility , BRCA1, has an interesting mechanism as a tumor suppressor," said Deborah Kelly, an assistant professor at the Virginia Tech Carilion Research Institute and senior author on the paper. "Unfortunately, where there are mutations in BRCA1, there's a significant decrease in its ability to repair DNA and cells are more likely to become cancerous."

Scientists knew the mutations promoted cancer, but they didn't know exactly how BRCA1 physically changed, or how those changes prevented the protein from participating in DNA repair.

Kelly and her team focused on a highly prevalent BRCA1 mutation to begin to understand not only the structural changes, but also the functional fallout. Using molecular imaging and biochemical tools, the researchers examined human and found that mutated BRCA1 proteins were destroyed under stressful, oxidative cellular conditions. The proteins were unable to properly repair damaged DNA.

"The system we use mimics the chain of events resulting from the inappropriate breakdown of estrogen, which produces molecules known as that can modify DNA and proteins, contributing to cancer," Kelly said.

Healthy cells can manage the damage caused by reactive oxygen species, also called free radicals, with repair proteins. Kelly and her team saw that typical BRCA1 proteins remained relatively stable, but mutated BRCA1 proteins significantly reduced in number.

Micrograph showing a lymph node invaded by ductal breast carcinoma, with extension of the tumour beyond the lymph node. Credit: Nephron/Wikipedia

Cells tag the mutated BRCA1 protein for destruction with a molecule called ubiquitin, according to Kelly. The cells then destroy the ubiquitin-tagged BRCA1 proteins, leading to a decrease in their ability to repair DNA lesions.

Kelly and her team are not the first to identify ubiquitination, but they are the first to recognize that the process increases in response to the BRCA1 mutation. They suspect that the BRCA1 mutation causes a small misfolding that allows even more ubiquitin to attach to the protein.

"Some ubiquitin modifications actually enhance the function of proteins, but, in this case, it acts as a target for degradation," said Kelly, who is also an assistant professor of biological sciences at Virginia Tech's College of Science. "Compared with non-mutated BRCA1 proteins, the ubiquitination process heightens the destruction of mutated BRCA1 proteins. The levels are lowered to a point where its power to assist in genomic maintenance is compromised."

The process of ubiquitation is already a target for a potential therapeutic treatment, according to Kelly. It's theoretically possible for enzymes to block or remove the ubiquitin, allowing cells to potentially enhance or restore BRCA1's function as a tumor suppressor.

"We demonstrated that protein levels, genetic mutations, and the chemical changes in proteins after they are made, known as post-translational modifications - particularly ubiquitination - can affect BRCA1's functional state in ," Kelly said. "Based on the results of this work, the next logical step is to test mechanistic-based therapies, such as enzymes that remove ubiquitin to restore the physical properties of the mutated BRCA1."

Current experiments in the Kelly Lab involve determining the 3D structures of healthy and mutated BRCA1 using high resolution cryo-electron microscopy.

This information may help scientists more fully understand the extent to which some individuals with BRCA1 mutations are more disposed to cancer than others, based on physical changes to the BRCA1 protein structure.

Explore further: Research explains the role of the gene BRCA1 in DNA repair

More information: Scientific Reports, DOI: 10.1038/srep43435

Related Stories

Research explains the role of the gene BRCA1 in DNA repair

May 30, 2016
Scientists at the University of Birmingham are a step closer to understanding the role of the gene BRCA1. Changes in this gene are associated with a high risk of developing breast and ovarian cancer.

Scientists uncover the structure of a protein complex linked with breast and ovarian cancer risk

January 11, 2017
Scientists at the Francis Crick Institute have described the molecular structure of a key tumour suppressor protein and provided insights into its role in cells.

Researchers discover BRCA1 gene is key for blood forming stem cells

January 24, 2017
Researchers at from the Harold C. Simmons Comprehensive Cancer Center have found that the BRCA1 gene is required for the survival of blood forming stem cells, which could explain why patients with BRCA1 mutations do not have ...

Changes in gene contribute independently to breast and ovarian cancer

January 31, 2017
Defects in a key gene - long thought to drive cancer by turning off the protection afforded by the well-known BRCA genes - spur cancer growth on their own, according to a study led by researchers from NYU Langone Medical ...

BRCA1 mutations in breast and ovarian cancer can predict treatment resistance

July 25, 2016
Mutations in the BRCA1 gene are one of the most common risk factors for breast and ovarian cancers. Although tumors that harbor BRCA1 mutations initially respond well to cancer treatments, many tumors eventually become less ...

Study uncovers mechanism used by BRCA1 to suppress tumors

December 17, 2012
A new study by Georgetown University Medical Center researchers reveals how a well-known tumor suppressor gene may be functioning to stop cancer cell growth.

Recommended for you

Fully reprogrammed virus offers new hope as cancer treatment

May 25, 2018
A cancer treatment that can completely destroy cancer cells without affecting healthy cells could soon be a possibility, thanks to research led by Cardiff University.

Research could help fine-tune cancer treatment

May 25, 2018
Cancer therapies that cut off blood supply to a tumour could be more effective in combination with existing chemotherapeutic drugs—according to new research from the University of East Anglia.

Increasing physical activity linked to better immunity in breast cancer patients, study finds

May 25, 2018
A new study from the University of Toronto's Faculty of Kinesiology & Physical Education has found that moderate to vigorous physical activity may help regulate the levels of C-reactive protein – an important biomarker ...

Low-fat diet tied to better breast cancer survival

May 24, 2018
(HealthDay)—Breast cancer patients who adopted a low-fat diet were more likely to survive for at least a decade after diagnosis, compared to patients who ate fattier fare, new research shows.

A cascade of immune processes offers insights to triple-negative breast cancer

May 24, 2018
Cancer is crafty. To survive and thrive, tumors find a way of thwarting our body's natural systems.

By forming clots in tumors, immune cell aids lung cancer's spread

May 24, 2018
University of North Carolina Lineberger Comprehensive Cancer Center researchers have found that by helping to form clots within tumors, immune cells that flock to a particular type of lung cancer are actually building a foundation ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.